SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.

Highlights Shenzhen Salubris Pharmaceuticals Co., Ltd.

Equities

002294

CNE100000FW8

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 2026-03-06			5-day change	1st Jan Change
50.81 ^CNY	+5.59%		+3.46%	+2.54%

Feb. 12	Salubris Pharmaceuticals Applies for Hong Kong Listing	MT
Feb. 12	Shenzhen Salubris submits listing application to Hong Kong stock exchange	RE

Highlights

Feb. 12	Salubris Pharmaceuticals Applies for Hong Kong Listing	MT
Feb. 12	Shenzhen Salubris submits listing application to Hong Kong stock exchange	RE
Jan. 22	Shenzhen Salubris Pharmaceuticals Gets Director Approval for Hong Kong Secondary Listing	MT
Jan. 22	China Stocks Gain After Trump Backs Down on Europe Tariffs; Salubris Closes 4% Lower	MT
Jan. 21	Shenzhen Salubris Pharmaceuticals plans to seek Hong Kong listing	RE
Jan. 11	Shenzhen Salubris Pharmaceuticals Gets Acceptance for Clinical Trial Application	MT
Jan. 07	Salubris Gets China Clinical Trial Nod for Fatty Liver Injection; Shares Rise 4%	MT
Dec. 11	Shenzhen Salubris Pharmaceuticals Plans Hong Kong IPO; Shenzhen Shares Slide 4%	MT
Dec. 11	Shenzhen Salubris Pharmaceuticals plans to seek Hong Kong listing	RE
Dec. 09	Salubris Pharmaceuticals' Three Drugs Placed in China's Medical Insurance Catalog	MT
Dec. 08	Salubris Pharmaceuticals Gets Nod to Trial Hyperaldosteronism Drug	MT
Dec. 03	Shenzhen Salubris Pharmaceuticals Gets China Approval for Chronic Kidney Disease Tablet Clinical Trials	MT
25-10-28	Salubris Pharmaceuticals Q3 Profit Up 31%, Revenue Rises 16%	MT
25-10-27	Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-16	Shenzhen Salubris Pharmaceuticals Gets Acceptance of Clinical Trial Application for Elevated Lipoprotein Drug	MT
25-09-30	Shenzhen Salubris Pharmaceuticals Gets Regulatory Acceptance for Clinical Trial Application	MT
25-08-20	Shenzhen Salubris Pharmaceuticals' Attributable Profit Jumps 6% in H1	MT
25-08-19	Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-05-28	Shenzhen Salubris Pharmaceuticals Gets Chinese Regulatory Approval for Hypertension Drug	MT
25-04-22	Shenzhen Salubris Pharmaceuticals Co., Ltd. Approves Final Cash Dividend on A Shares for 2024, Payable on May 14, 2025	CI
25-04-22	Shenzhen Salubris Pharmaceuticals' Q1 Profit Stays Flat	MT
25-04-21	Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-03-31	Shenzhen Salubris Pharmaceuticals Co., Ltd. Proposes Final Cash Dividend for the Year 2024	CI
25-03-28	Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-02-14	Chinese Drug Regulator Accepts Salubris Pharmaceuticals' Application to Trial Hypertension Drug	MT